Dr. Andrew Newberg is the director of research at the Marcus Institute of Integrative Health and a physician at Jefferson University Hospital. He is board certified in internal medicine and nuclear medicine. He is a neuroscientist who studies the relationship between brain function and various mental states. He is a pioneer in the neurological study of religious and spiritual experiences, a field known as “neurotheology.” His research includes taking brain scans of people in prayer, meditation, rituals, and trance states, in an attempt to better understand the nature of religious and spiritual practices and attitudes. Andrew has also used neuroimaging research projects to study aging and dementia, Parkinson’s disease, epilepsy, depression, and other neurological and psychiatric disorders.
Dr. Prause received her Doctorate in Clinical Science from Indiana University, Bloomington. After an internship in 2007, she started a tenure-track position at Idaho State University, left for a Research Scientist position at Mind Research Network, and ultimately landed at UCLA in the Department of Psychiatry. She has since founded an independent, grant-funded research institute, Liberos, in Los Angeles. The focus of Liberos is to identify the general health benefits of sexual stimulation.
Dr. Siegel has served as editor of leading scientific journals, including Cell and PLOS Biology, founded and directed the Center for Science Communication (CSC) at Vanderbilt University, and led communications and education and outreach initiatives at the Broad Institute of MIT and Harvard. She currently serves as a lecturer of biology at MIT.
Dr. Siegle directs the Program in Cognitive Affective Neuroscience (PICAN) at the University of Pittsburgh School of Medicine, where he is a Professor of Psychiatry, Psychology, and Translational Sciences. His research examines neural mechanisms of emotional and cognitive information processing in mood and anxiety disorders, how this information can be used to predict response to treatment, and to guide novel treatment development.